Table 3.
Antibiotic susceptibility patterns of gram-negative bacteria isolated from sanandaj hospitals, Iran, 2012 (% susceptible)
| Escherichia coli | Klebsiella pneumoniae | Klebsiella oxytoca | Serratia marcescens | Serratia ordorifera | Acinetobacter | Species enterobacter | Pseudomonas aeruginosa | Pseudomonas orizihibitans | Pseudomonas luteola | Stenotropho-monas | Suscepti bility of all Isolates | No. of isolates tested | |
| Ampicillin | 1 (6.7) | 3 (20) | 0 (0) | 1 (3.3) | 0 (0) | 0 (0) | 0 (0) | - | - | - | - | 5 (6.7) | 74 |
| Amoxicillin | 2 (13.3) | 1 (6.7) | 0 (0) | 1 (3.3) | 0 (0) | 0 (0) | 1 (20) | - | - | - | - | 5 (6.7) | 74 |
| Amikacin | 14 (93.3) | 8 (53.3) | 1 (100) | 23 (76.7) | 2 (66.7) | 2 (40) | 4 (80) | 2 (100) | 1 (100) | 1 (100) | 1 (100) | 58 (73.4) | 79 |
| Gentamicin | 11 (73.3) | 7 (46.7) | 0 (0) | 22 (73.3) | 1 (33.3) | 0 (0) | 4 (80) | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 48 (60.7) | 79 |
| Tobramycin | - | - | - | - | - | - | - | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 4 (80) | 5 |
| Cotrimoxazole | 2 (13.3) | 6 (40) | 0 (0) | 21 (70) | 2 (66.7) | 1 (20) | 4 (80) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 36 (45.5) | 79 |
| Nitrofurantoin | 15 (100) | 10 (66.7) | 0 (0) | 6 (20) | 2 (66.7) | 0 (0) | 3 (60) | - | - | - | - | 35 (47.2) | 74 |
| Cephalothin | 6 (40) | 5 (33.3) | 0 (0) | 1 (3.3) | 1 (33.3) | 0 (0) | 1 (20) | - | - | - | - | 13 (17.6) | 74 |
| Cefixime | 10 (66.7) | 5 (33.3) | 0 (0) | 22 (73.3) | 1 (33.3) | 0 (0) | 2 (40) | - | - | - | - | 39 (52.7) | 74 |
| Cefotaxime | 9 (60) | 5 (33.3) | 0 (0) | 22 (73.3) | 1 (33.3) | 0 (0) | 4 (80) | - | - | - | - | 40 (54) | 74 |
| Ceftazidim | 11 (73.3) | 5 (33.3) | 0 (0) | 24 (80) | 2 (66.7) | 0 (0) | 4 (80) | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 49 (62) | 79 |
| Ceftriaxone | 8 (53.3) | 6 (40) | 0 (0) | 22 (73.3) | 1 (33.3) | 0 (0) | 3 (60) | - | - | - | - | 39 (52.7) | 74 |
| Cefepim | 13 (86.7) | 7 (46.7) | 0 (0) | 24 (80) | 3 (100) | 0 (0) | 4 (80) | 1 (50) | 1 (100) | 1 (100) | 0 (0) | 52 (65.8) | 79 |
| Ciprofloxacin | 11 (73.3) | 13 (86.7) | 0 (0) | 30 (100) | 3 (100) | 1 (20) | 4 (80) | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 65 (82.3) | 79 |
| Levofloxacin | 11 (73.3) | 13 (86.7) | 0 (0) | 30 (100) | 3 (100) | 1 (20) | 5 (100) | 2 (100) | 1 (100) | 1 (100) | 1 (100) | 67 (84.8) | 79 |
| Imipenem | 15 (100) | 15 (100) | 1 (100) | 30 (100) | 3 (100) | 5 (100) | 5 (100) | 2 (100) | 1 (100) | 1 (100) | 1 (100) | 79 (100) | 79 |
| Meropenem | - | - | - | - | - | - | - | 2 (100) | 1 (100) | 1 (100) | 1 (100) | 5 (100) | 5 |
| Carbenicillin | - | - | - | - | - | - | - | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 4 (80) | 5 |
| Ticarcillin | - | - | - | - | - | - | - | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 4 (80) | 5 |
| Piperacillin | - | - | - | - | - | - | - | 2 (100) | 1 (100) | 1 (100) | 0 (0) | 4 (80) | 5 |
| Piperacillin/ Tazobactam | 10 (66.7) | 13 (86.7) | 1 (100) | 27 (90) | 3 (100) | 0 (0) | 4 (80) | 2 (100) | 1 (100) | 1 (100) | - | 57 (73) | 78 |
| Aztreonam | - | - | - | - | - | - | - | 2 (100) | 1 (100) | 1 (100) | - | 3 (75) | 4 |
| ESBL(positive) | 5 (33.3)1 | 10 (66.7)1 | - | - | - | - | - | - | - | - | - | 16 (51.6)1 | 311 |
| Total susceptible isolates (%) | 149 (62.1) | 122 (50.8) | 3 (18.7) | 306 (63.7) | 28 (58.3) | 10 (12.5) | 52 (65) | 27 (90) | 14 (93.3) | 14 (93.3) | 4 (30.7) | 711 (56.6)2 | -- |
| Total isolates tested (sum) | 240 | 240 | 16 | 480 | 48 | 80 | 80 | 30 | 15 | 15 | 13 | -- | 1257 |
1
Not counted in the sum and susceptibility percents;
2
Total sensitive Isolates (% susceptibility of total tested isolates).